Therapeutic delivery最新文献_第5页

Exploring the potential of multiple receptors overexpressed on glioblastoma cells as biomarkers for the targeted therapy; a review. 探索胶质母细胞瘤细胞上多受体过表达作为靶向治疗生物标志物的潜力；复习一下。

IF 3.4

Therapeutic delivery Pub Date : 2026-05-01 Epub Date: 2026-06-11 DOI: 10.1080/20415990.2026.2682697

Saqib Hussain Hadri, Muhammad Hassnain, Rohab Gul, Shayan Waleed Basharat, Ayesha Mahmood, Warda Kashif, Hammad Ismail

{"title":"Exploring the potential of multiple receptors overexpressed on glioblastoma cells as biomarkers for the targeted therapy; a review.","authors":"Saqib Hussain Hadri, Muhammad Hassnain, Rohab Gul, Shayan Waleed Basharat, Ayesha Mahmood, Warda Kashif, Hammad Ismail","doi":"10.1080/20415990.2026.2682697","DOIUrl":"10.1080/20415990.2026.2682697","url":null,"abstract":"Glioblastoma multiforme (GBM), due to its complex and highly heterogeneous nature, remains one of the deadliest cancers in the world. However, advances in targeted therapy offer hope for improved GBM treatment through extensive research into receptor-mediated targeting approaches that exploit receptors overexpressed on the surface of GBM cells, including interleukin-13 receptor alpha 2 (IL-13Rα2), transferrin receptor (TfR), receptor tyrosine kinases (RTKs), and integrins. Nanoparticles such as liposomes, lactoferrin-based specialized nanocarriers, and gold nanoparticles functionalized with targeting ligands including Pep-1L, lactoferrin, and RGD peptides, and loaded with anticancer drugs such as temozolomide, gefitinib, and epirubicin, are being explored for targeted GBM therapy. These approaches have demonstrated promising preclinical outcomes, with several formulations in early-phase clinical trials to evaluate safety, pharmacokinetics, and therapeutic efficacy. Certain receptors, including periostin (POSTN) and chondroitin sulfate proteoglycan-4 (CSPG4), involved in tumor invasion, glioma stemness, and therapeutic resistance, remain relatively underexplored, presenting opportunities for further research. Despite these advances, clinical translation remains limited by nanoparticle-associated cytotoxicity and off-target effects. This highlights the need for future research focused on developing biodegradable and biocompatible nanomaterials, along with optimized ligand-guided designs, to improve safety and enhance translational feasibility in glioblastoma therapy. Literature search Methodology: [PubMed and Google Scholar; 2006-2026].","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"467-480"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148219841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 3.4

Therapeutic delivery Pub Date : 2026-05-01 Epub Date: 2025-10-20 DOI: 10.1080/20415990.2025.2577025

引用次数: 0

An evaluation of aripiprazole long-acting injectable monthly and bimonthly in the maintenance treatment of bipolar I disorder. 阿立哌唑长效注射每月和双月治疗双相I型障碍的疗效评价。

IF 3.4

Therapeutic delivery Pub Date : 2026-05-01 Epub Date: 2026-06-25 DOI: 10.1080/20415990.2026.2692883

Maria-Christina Sioufi, Christine E Dri, Roger S McIntyre

{"title":"An evaluation of aripiprazole long-acting injectable monthly and bimonthly in the maintenance treatment of bipolar I disorder.","authors":"Maria-Christina Sioufi, Christine E Dri, Roger S McIntyre","doi":"10.1080/20415990.2026.2692883","DOIUrl":"10.1080/20415990.2026.2692883","url":null,"abstract":"Bipolar disorder (BD) is a chronic and severe mental disorder with a high risk for recurrence, requiring long-term mood stabilization treatment approaches. The hazards of recurrence in BD include illness progression, decreasing treatment response, chronicity, comorbidity, suicidality, increased health service utilization, and greater direct and indirect economic costs. Treatment nonadherence is one of the most common modifiable deficiencies in the maintenance treatment of BD, which exacerbates the risk of recurrence and unfavorable course and outcome. Aripiprazole is the only dopamine partial agonist that is FDA-approved in a long-acting injectable (LAI) formulation for the maintenance treatment of adults with bipolar I disorder (BD-I), offered as both a once-monthly and bimonthly monohydrate. Herein, we synthesize the results supporting the efficacy, safety, and tolerability of both aripiprazole LAI formulations in BD-I. A narrative search was conducted by an expert opinion in the field, as well as targeted bibliographic searching. Both aripiprazole LAI formulations were established as efficacious in the reduction of manic and mixed episodes in adults with BD-I; however, their efficacy for bipolar depression prevention remains unproven. Aripiprazole LAI is well tolerated and safe, with injection site pain, sedation, weight increase, and akathisia being the most common adverse events.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"435-444"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Damp scalp application enhances follicular delivery of dutasteride loaded in liposomes compared to dry scalp. 与干燥头皮相比，潮湿头皮应用增强了脂质体中杜他雄胺的毛囊输送。

IF 3.4

Therapeutic delivery Pub Date : 2026-05-01 Epub Date: 2026-06-19 DOI: 10.1080/20415990.2026.2689842

Geisa N Barbalho, Breno N Matos, Jayanaraian F M Andrade, Zahra Aragui, Marcilio Cunha-Filho, Guilherme M Gelfuso, Tais Gratieri

{"title":"Damp scalp application enhances follicular delivery of dutasteride loaded in liposomes compared to dry scalp.","authors":"Geisa N Barbalho, Breno N Matos, Jayanaraian F M Andrade, Zahra Aragui, Marcilio Cunha-Filho, Guilherme M Gelfuso, Tais Gratieri","doi":"10.1080/20415990.2026.2689842","DOIUrl":"10.1080/20415990.2026.2689842","url":null,"abstract":"Dutasteride (DUT) has been increasingly investigated to treat androgenic alopecia topically to minimize systemic side effects. Given evidence that scalp hydration influences drug skin penetration, this study assessed whether applying a DUT-loaded liposome formulation to damp skin enhances DUT deposition compared to dry skin. Skin samples were shampoo-cleansed and either towel-dried or air-dried, followed by treatment with a DUT-loaded liposome formulation. DUT delivery was evaluated in vitro using a modified Saarbrücken model on rodent and porcine skin, with quantification of drug accumulation in viable skin and hair follicles after 12 hours. In rat skin, DUT follicular accumulation nearly doubled on damp skin samples (9.4 ± 1.8 μg/cm2) relative to dry skin (4.7 ± 1.2 μg/cm2, p < 0.05), attributed to enhanced moisture retention in the high follicular density model, which facilitated diffusion. Conversely, porcine skin showed comparable values for damp (10.0 ± 2.1 μg/cm2) and dry (11.8 ± 2.9 μg/cm2) skin conditions, consistent with its lower follicular density and limited capacity to sustain hydration. These findings demonstrate that scalp hydration status can critically modulate topical DUT delivery, particularly in follicle-rich models. Establishing application guidelines considering scalp moisture may improve the clinical performance of topical DUT formulations.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"405-417"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148278864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current modeling approaches for drug delivery to the central nervous system. 当前药物输送到中枢神经系统的建模方法。

IF 3.4

Therapeutic delivery Pub Date : 2026-05-01 Epub Date: 2026-06-05 DOI: 10.1080/20415990.2026.2682695

Shoaib A Goraya, Abraham R Tzafriri, Charles R G Guttmann, Farhad R Nezami

{"title":"Current modeling approaches for drug delivery to the central nervous system.","authors":"Shoaib A Goraya, Abraham R Tzafriri, Charles R G Guttmann, Farhad R Nezami","doi":"10.1080/20415990.2026.2682695","DOIUrl":"10.1080/20415990.2026.2682695","url":null,"abstract":"Central nervous system (CNS) disorders pose a major global health challenge, yet therapeutic development is impeded by the difficulty of delivering effective drug concentrations to the brain. Based on a literature search of PubMed, Scopus, and Google Scholar (1990-2025), this review delineates the current landscape of computational modeling techniques addressing CNS drug delivery, emphasizing anatomical barriers and physiological transport mechanisms relevant to major neurological diseases. We categorize approaches spanning the molecular dynamics interactions of drug-blood-brain barrier (BBB) to macroscopic continuum and physiologically based pharmacokinetic (PBPK) models that elucidate systemic distribution and brain exposure. These models are assessed across established delivery routes, such as intranasal and intrathecal administration, and emerging methods, including focused ultrasound-mediated BBB opening and targeted nanoparticle delivery. We highlight the growing importance of integrating complex physiological phenomena, such as glymphatic flow and cerebrospinal fluid (CSF) dynamics, into predictive models. Finally, we explore opportunities involving multiscale digital twins of the CNS that integrate molecular interactions, vascular hemodynamics, perivascular flow, and parenchymal transport within patient-specific geometries. We also examine the role of machine learning and surrogate modeling in accelerating prediction of drug transport parameters and optimizing delivery strategies, aiming to guide the design of robust computational platforms.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"445-466"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statistical optimization and characterization of diacerein-loaded Eudragit S-100 nanoparticles using a 3² factorial design for rheumatoid arthritis therapy. 利用32因子设计，统计优化和表征负载二乙酰二酚的Eudragit S-100纳米颗粒用于类风湿关节炎治疗。

IF 3.4

Therapeutic delivery Pub Date : 2026-05-01 Epub Date: 2026-06-09 DOI: 10.1080/20415990.2026.2682703

Susanta Paul, Dibya Sinha, Ishita Sarkar, Swarupananda Mukherjee, Sakuntala Gayen, Souvik Roy, Soumendra Nath Bandyopadhyay, Pasquale De Toro, Rajesh Kesarla

{"title":"Statistical optimization and characterization of diacerein-loaded Eudragit S-100 nanoparticles using a 32 factorial design for rheumatoid arthritis therapy.","authors":"Susanta Paul, Dibya Sinha, Ishita Sarkar, Swarupananda Mukherjee, Sakuntala Gayen, Souvik Roy, Soumendra Nath Bandyopadhyay, Pasquale De Toro, Rajesh Kesarla","doi":"10.1080/20415990.2026.2682703","DOIUrl":"10.1080/20415990.2026.2682703","url":null,"abstract":"Aims: This study focused on developing an effective Rheumatoid Arthritis (RA) treatment by creating diacerein-loaded nanoparticles. The goal was to create a more efficient RA treatment with fewer side effects, something conventional treatments fail to achieve.Materials and methods: Using the solvent evaporation technique, the researchers produced nanoparticles and formulated them, which they optimized using DOE (Design of Experiments). They also analyzed their nanoparticle formulations through three methods: particle size, entrapment efficiency, and in vitro drug release.Results: Their results indicate controlled drug release and desirable physical-chemical properties that should lead to greater bioavailability, which is a good thing because it leads to less waste. The in-vitro studies show that when using diacerein delivered through nanoparticles, there will be a greater anti-inflammatory response from chondrocytes than if diacerein were administered alone.Conclusions: Therefore, this study provides evidence that nanoparticles can be used to treat RA, improving drug effectiveness, decreasing systemic toxicity, and improving patient compliance.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"395-404"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148210998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eudragit E100/silk fibroin hybrid nanoparticles for the controlled oral delivery of amphotericin B. E100/丝素混合纳米颗粒用于两性霉素B的口服控制。

IF 3.4

Therapeutic delivery Pub Date : 2026-04-01 Epub Date: 2026-04-30 DOI: 10.1080/20415990.2026.2665555

Duy Toan Pham, Pham Thi Thuy Loan, Phuong T M Ha, Ngoc Yen Nguyen, Huynh Vu Thanh Luong, Nguyen Trong Tuan, Bui Thi Phuong Thuy

{"title":"Eudragit E100/silk fibroin hybrid nanoparticles for the controlled oral delivery of amphotericin B.","authors":"Duy Toan Pham, Pham Thi Thuy Loan, Phuong T M Ha, Ngoc Yen Nguyen, Huynh Vu Thanh Luong, Nguyen Trong Tuan, Bui Thi Phuong Thuy","doi":"10.1080/20415990.2026.2665555","DOIUrl":"10.1080/20415990.2026.2665555","url":null,"abstract":"Aims: Amphotericin B (AmB) is the first-line antifungal compound for severe fungal infections, yet it possesses high renal toxicity, low water solubility, and acidic instability in the stomach. Herein, we developed novel nanoparticles from silk fibroin with/without Eudragit E100 (FNP and FNP/EE) for the controlled oral delivery of AmB.Methods and results: The particles were formulated by two different methods of co-condensation and adsorption, which yielded comparable particle sizes of ~1500 nm (FNP-AmB) and ~800 nm (FNP/EE-AmB) and AmB entrapment efficiencies of >70%. AmB was rapidly adsorbed onto the particles by physical processes, which followed the Langmuir and Dubinin-Radushkevich isotherm models and Weber-Morris intraparticle diffusion model. The particles structures were confirmed by the FT-IR, DSC, and XRD spectra. The particles effectively protected AmB in the gastric environment, with limited AmB releases (<20%), and controlled AmB releases in the intestines, followed Korsmeyer-Peppas model. Moreover, AmB was encapsulated in partial aggregated form, with was less toxic than the free AmB; and the particles showed no hematotoxicity and adequate in vitro antifungal activity.Conclusions: The particles solved the AmB limitations by (1) protecting AmB from the gastric environment, (2) controlling AmB release, (3) reducing AmB toxicity, and (4) preserving AmB efficacy.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"283-296"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Industry update January 2026. 行业更新2026年1月。

IF 2.2

Therapeutic delivery Pub Date : 2026-04-01 Epub Date: 2026-03-16 DOI: 10.1080/20415990.2026.2642516

Louise Rosenmayr-Templeton

引用次数: 0

Glycolic acid-integrated nanostructured lipid carriers of apremilast and quercetin co-delivery for the management of psoriasis. 乙醇酸集成的纳米结构脂质载体阿普雷米司特和槲皮素共同递送治疗牛皮癣。

IF 3.4

Therapeutic delivery Pub Date : 2026-04-01 Epub Date: 2026-04-28 DOI: 10.1080/20415990.2026.2662182

Amit Sharma, Raj Kumar Narang, Balak Das Kurmi

{"title":"Glycolic acid-integrated nanostructured lipid carriers of apremilast and quercetin co-delivery for the management of psoriasis.","authors":"Amit Sharma, Raj Kumar Narang, Balak Das Kurmi","doi":"10.1080/20415990.2026.2662182","DOIUrl":"10.1080/20415990.2026.2662182","url":null,"abstract":"Aim: The goal of this study was to develop and optimize glycolic acid integrated nanostructured lipid carriers (NLCs).Methods: The developed NLCs were optimized by 34 Central Composite Design (CCD) and were evaluated for their particle size, polydispersity index (PDI), zeta-potential, drug loading, and entrapment efficiency. Moreover, in-vitro drug release, ex-vivo skin permeation and retention analysis, cytocompatibility using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, antioxidant measurements via DPPH (2,2-diphenyl-1-picrylhydrazyl) scavenging assessment for anti-inflammatory effects by observing cytokine inhibition in lipopolysaccharide (LPS)-stimulated macrophages, and in-vivo irritation potential using the Hen's Egg Test on the Chorioallantoic Membrane (HET-CAM) assay were also evaluated.Results: The optimized NLCs have a particle size of 121.75 ± 9.18 nm, a PDI of 0.367 ± 0.07, and a zeta potential of -35.77 ± 3.44 mV, indicating a stable formulation. In-vitro assays demonstrated sustained drug release, cytocompatibility, and antioxidant potency with effective reduction of pro-inflammatory cytokines, i.e. interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α).Conclusion: The combined Apremilast (APM)-Quercetin (QRC)-NLC integrated with glycolic acid introduces an promising nanocarrier strategy for the topical treatment of psoriasis.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"265-282"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

QbD-guided development and optimization of a rapid-disintegrating sublingual film of olanzapine. qbd引导下快速崩解奥氮平舌下膜的研制与优化。

IF 3.4

Therapeutic delivery Pub Date : 2026-04-01 Epub Date: 2026-04-30 DOI: 10.1080/20415990.2026.2665559

Devendra Patil, Bappaditya Chatterjee, Jagannath Sahoo, Rohan Pai

{"title":"QbD-guided development and optimization of a rapid-disintegrating sublingual film of olanzapine.","authors":"Devendra Patil, Bappaditya Chatterjee, Jagannath Sahoo, Rohan Pai","doi":"10.1080/20415990.2026.2665559","DOIUrl":"10.1080/20415990.2026.2665559","url":null,"abstract":"Aim: Olanzapine is an atypical antipsychotic used to treat chronic schizophrenia and bipolar I disorder, including mixed/manic episodes. It is a BCS class II medication, and thus there is a potential for sublingual administration allowing rapid absorption. This may potentially result in a faster onset of action compared to oral tablets. The aim of this work was to formulate a fast-dissolving sublingual film of olanzapine with rapid disintegration.Materials and methods: Hydroxypropyl methylcellulose E5, polyethylene glycol 400, and Transcutol HP were optimized using a QBD approach based on disintegration time, folding endurance, weight variation, content uniformity, and in vitro drug release of films.Results: The drug was completely soluble with the above-mentioned ingredients. Optimized film was further evaluated for drug content, pH, and dissolution studies. The optimized film disintegrated within 30 s, showed smooth surfaces on SEM and AFM analysis. The drug content was found to be 88% for optimized film formulation, and the in vitro dissolution studies estimated the release to be 94.79% in 10 min.Conclusion: This novel approach may offer a promising alternative in terms of reduced dosage; however, further investigations and in vivo assessment of the film are warranted to prove enhanced permeation indicating quicker absorption sublingually, leading to an increase in bioavailability.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"297-312"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0